Literature DB >> 23670805

Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.

Paul Avillach1, Francesco Salvo, Frantz Thiessard, Ghada Miremont-Salamé, Annie Fourrier-Reglat, Françoise Haramburu, Bernard Bégaud, Nicholas Moore, Antoine Pariente.   

Abstract

PURPOSE: To test an automated method to decrease the number of false-positive (FP) signals of disproportionate reportings (SDRs) generated by co-prescription.
METHODS: Automated backward stepwise removal of reports concerning the drug associated with the highest ranked SDR for an event was tested for gastric and oesophageal haemorrhages (GOH), central nervous system haemorrhages and cerebrovascular accidents (CNSH), ischaemic coronary artery disorders and muscle pains (MP) using the reporting odds ratio in the French spontaneous reporting research database. After ranking SDRs detected in the complete dataset on the lower limit of the reporting odds ratio 95% confidence interval, reports concerning the drug with the highest ranked SDR were removed. In the dataset thus generated, SDRs were again identified, ranked and reports related to the drug involved in the newly highest ranked SDR removed. The process was repeated until no signal was detected. Initially detected SDRs eliminated using this technique were assessed regarding the summary of products characteristics and the literature to determine their FP nature.
RESULTS: Seventeen SDRs were successively eliminated for GOH, 37 for CNSH, 15 for ischaemic coronary artery disorders, and 36 for MP. Four were FP for GOH, 29 for CNSH, 7 for ACI and none were FP for MP. The positive predictive value of the backward stepwise removal procedure in identifying FP SDRs ranged from 0% (MP) to 78.4% (CNSH).
CONCLUSIONS: Although further adjustment is needed to improve the method presented herein, our results suggest that numerous FP signals because of co-prescription bias could be eliminated using an automated method.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adverse reaction; bias; methods; pharmacoepidemiology; pharmacovigilance; signal detection; spontaneous reporting

Mesh:

Substances:

Year:  2013        PMID: 23670805     DOI: 10.1002/pds.3454

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation.

Authors:  Francesco Salvo; Emanuel Raschi; Ugo Moretti; Anita Chiarolanza; Annie Fourrier-Réglat; Nicholas Moore; Miriam Sturkemboom; Fabrizio De Ponti; Elisabetta Poluzzi; Antoine Pariente
Journal:  Eur J Clin Pharmacol       Date:  2014-03-05       Impact factor: 2.953

2.  Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database.

Authors:  Ryuichiro Hosoya; Yoshihiro Uesawa; Reiko Ishii-Nozawa; Hajime Kagaya
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

3.  Network Analysis for Signal Detection in Spontaneous Adverse Event Reporting Database: Application of Network Weighting Normalization to Characterize Cardiovascular Drug Safety.

Authors:  Bence Ágg; Péter Ferdinandy; Mátyás Pétervári; Bettina Benczik; Olivér M Balogh; Balázs Petrovich
Journal:  Drug Saf       Date:  2022-10-06       Impact factor: 5.228

4.  The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Francesco Salvo; Ariola Koci; Marc Suling; Stefania Antoniazzi; Luisella Perina; Lorna Hazell; Ugo Moretti; Miriam Sturkenboom; Edeltraut Garbe; Antoine Pariente; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

5.  Analysis of Factors Associated with Hiccups Using the FAERS Database.

Authors:  Ryuichiro Hosoya; Reiko Ishii-Nozawa; Kota Kurosaki; Yoshihiro Uesawa
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.